

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number  
WO 01/23362 A2

(51) International Patent Classification<sup>7</sup>: C07D 239/48,  
251/18, 239/50, 403/12, 521/00, 405/14, A61K 31/505,  
A61P 35/00

Dannstadt (DE). ROSENBERG, Jörg [DE/DE]; Bruch-  
strasse 29, 67158 Ellerstadt (DE). BREITENBACH, Jörg  
[DE/DE]; Hans-Sachs-Ring 95A, 68199 Mannheim (DE).

(21) International Application Number: PCT/EP00/09149

(74) Agent: GOLDSCHEID, Bettina; BASF Aktien-  
sellschaft, 67056 Ludwigshafen (DE).

(22) International Filing Date:  
19 September 2000 (19.09.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(30) Priority Data:  
199 45 982.7 24 September 1999 (24.09.1999) DE

(84) Designated States (regional): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).


(71) Applicant (for all designated States except US): KNOLL  
AKTIENGESELLSCHAFT [DE/DE]; 67061 Ludwigshafen (DE).

Published:  
— Without international search report and to be republished  
upon receipt of that report.

(72) Inventors; and


For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(75) Inventors/Applicants (for US only): HANTKE, Thomas  
[DE/DE]; Landauerstrasse 5, 67067 Ludwigshafen (DE).  
REHBOCK, Bettina [DE/DE]; Wasgauring 28, 67125



(54) Title: RATE-CONTROLLED PARTICLES

WO 01/23362 A2



(57) Abstract: Rate-controlled  
particles, comprising compounds of  
formula (I) as a solid dispersion.

## Rate-controlled particles


## Specification

5

The present invention concerns pharmaceutical compositions in the form of rate-controlled particles, comprising compounds of the formula (I) to (VI)

10 (I) is an antiviral compound of formula

15



a N-oxide, a pharmaceutically acceptable addition salt or a  
20 stereochemically isomeric form thereof, wherein

Y is CR<sup>5</sup> or N;

A is CH, CR<sup>4</sup> or N;

n is 0, 1, 2, 3 or 4;

25 Q is -NR<sup>1</sup>R<sup>2</sup> or when Y is CR<sup>5</sup> then Q may also be hydrogen;

R<sup>1</sup> and R<sup>2</sup> are each independently selected from hydrogen, hydroxy, C<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkyloxy, C<sub>1-12</sub>alkylcarbonyl, C<sub>1-12</sub>alkyloxycarbonyl, aryl, amino, mono- or di(C<sub>1-12</sub>alkyl)-amino, mono- or di(C<sub>1-12</sub>alkyl)aminocarbonyl wherein each of

30 the aforementioned C<sub>1-12</sub>alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C<sub>1-6</sub>alkyloxy, hydroxy-C<sub>1-6</sub>alkyloxy, carboxyl, C<sub>1-6</sub>alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or

35 di(C<sub>1-6</sub>alkyl)amino, aryl and Het; or

R<sup>1</sup> and R<sup>2</sup> taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C<sub>1-12</sub>alkyl)aminoC<sub>1-4</sub>-alkylidene;

40 R<sup>3</sup> is hydrogen, aryl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy-carbonyl, C<sub>1-6</sub>alkyl substituted with C<sub>1-6</sub>alkyloxycarbonyl; and each R<sup>4</sup> independently is hydroxy, halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalo-methyloxy, or when Y is CR<sup>5</sup> then R<sup>4</sup> may also represent C<sub>1-6</sub>alkyl substituted with cyano or aminocarbonyl;

45 R<sup>5</sup> is hydrogen or C<sub>1-4</sub>alkyl;

L is -X<sup>1</sup>-R<sup>6</sup> or -X<sup>2</sup>-Alk-R<sup>7</sup> wherein

R<sup>6</sup> and R<sup>7</sup> each independently are phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyloxycarbonyl, formyl, cyano, nitro, amino, and trifluoromethyl; or when Y is CR<sup>5</sup> then R<sup>6</sup> and R<sup>7</sup> may also be selected from phenyl substituted with one, two, three, four or five substituents each independently selected from aminocarbonyl, trihalomethyloxy and trihalomethyl; or when Y is N then R<sup>6</sup> and R<sup>7</sup> may also be selected from indanyl or indolyl, each of said indanyl or indolyl may be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyloxycarbonyl, formyl, cyano, nitro, amino, and trifluoromethyl;

10 X<sup>1</sup> and X<sup>2</sup> are each independently -NR<sup>3</sup>-, -NH-NH-, -N=N-, -O-, -S-, -S(=O)- or -S(=O)<sub>2</sub>;

15 Alk is C<sub>1-4</sub>alkanediyl; or

when Y is CR<sup>5</sup> then L may also be selected from C<sub>1-10</sub>alkyl,

20 C<sub>3-10</sub>alkenyl, C<sub>3-10</sub>alkynyl, C<sub>3-7</sub>cycloalkyl, or C<sub>1-10</sub>alkyl substituted with one or two substituents independently selected from C<sub>3-7</sub>cycloalkyl, indanyl, indolyl and phenyl, wherein said phenyl, indanyl and indolyl may be substituted with one, two, three, four or where possible five substituents each independently selected from halo, hydroxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, C<sub>1-6</sub>alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl, trihalomethyloxy and C<sub>1-6</sub>alkylcarbonyl;

25 aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, nitro and trifluoromethyl;

30 Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl,


35 tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy.

40

The compounds of formula (I) can be prepared according to the methods described in the patent applications with application number PCT/EP99/02043 and PCT/EP99/02044.

(II) is an antiviral compound of formula

5



10 the *N*-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein

-b¹ = b² - C(R²a) = b³ - b⁴ = represents a bivalent radical of formula

-CH=CH-C(R²a)=CH-CH= (b-1);

15 -N=CH-C(R²a)=CH-CH= (b-2);

-CH=N-C(R²a)=CH-CH= (b-3);

-N=CH-C(R²a)=N-CH= (b-4);

-N=CH-C(R²a)=CH-N= (b-5);

-CH=N-C(R²a)=N-CH= (b-6);

20 -N=N-C(R²a)=CH-CH= (b-7);

q is 0, 1, 2; or where possible q is 3 or 4;


R¹ is hydrogen, aryl, formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxycarbonyl, C<sub>1-6</sub>alkyl substituted with formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyloxycarbonyl;

25 R²a is cyano, aminocarbonyl, mono- or di(methyl)aminocarbonyl, C<sub>1-6</sub>alkyl substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl, C<sub>2-6</sub>alkenyl substituted with cyano, or C<sub>2-6</sub>alkynyl substituted with cyano;

each R² independently is hydroxy, halo, C<sub>1-6</sub>alkyl optionally substituted with cyano or -C(=O)R⁶, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl optionally substituted with one or more halogen atoms or cyano, C<sub>2-6</sub>alkynyl optionally substituted with one or more halogen atoms or cyano, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C<sub>1-6</sub>alkyl)amino,

35 polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)<sub>p</sub>R⁶, -NH-S(=O)<sub>p</sub>R⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH<sub>2</sub>, -NHC(=O)R⁶, -C(=NH)R⁶ or a radical of formula

40



wherein each A independently is N, CH or CR⁶;

B is NH, O, S or NR⁶;

45 p is 1 or 2; and

R⁶ is methyl, amino, mono- or dimethylamino or polyhalomethyl;

L is  $C_{1-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{3-7}$ cycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from

\*  $C_{3-7}$ cycloalkyl,

5 \* indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo,  $C_{1-6}$ alkyl, hydroxy,  $C_{1-6}$ alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethoxy and  $C_{1-6}$ alkylcarbonyl,

10 \* phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in  $R^2$ ; or

15 L is  $-X-R^3$  wherein  
 $R^3$  is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in  $R^2$ ; and

20 X is  $-NR^1-$ ,  $-NH-NH-$ ,  $-N=N-$ ,  $-O-$ ,  $-C(=O)-$ ,  $-CHOH-$ ,  $-S-$ ,  $-S(=O)-$  or  $-S(=O)_2-$ ;

Q represents hydrogen,  $C_{1-6}$ alkyl, halo, polyhalo $C_{1-6}$ alkyl or  $-NR^4R^5$ ; and

25  $R^4$  and  $R^5$  are each independently selected from hydrogen, hydroxy,  $C_{1-12}$ alkyl,  $C_{1-12}$ alkyloxy,  $C_{1-12}$ alkylcarbonyl,  $C_{1-12}$ alkyloxy-carbonyl, aryl, amino, mono- or di( $C_{1-12}$ alkyl)amino, mono- or di( $C_{1-12}$ alkyl)aminocarbonyl wherein each of the aforementioned  $C_{1-12}$ alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy,  $C_{1-6}$ alkyloxy, hydroxy $C_{1-6}$ alkyloxy, carboxyl,  $C_{1-6}$ alkyloxycarbonyl, cyano, amino, imino, mono- or di( $C_{1-6}$ alkyl)amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio,  $-S(=O)_pR^6$ ,  $-NH-S(=O)_pR^6$ ,  $-C(=O)R^6$ ,  $-NHC(=O)H$ ,  $-C(=O)NHNNH_2$ ,  $-NHC(=O)R^6$ ,  $-C(=NH)R^6$ , aryl and Het; or

30  $R^4$  and  $R^5$  taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di( $C_{1-12}$ alkyl)amino $C_{1-4}$ alkylidene;

35 Y represents hydroxy, halo,  $C_{3-7}$ cycloalkyl,  $C_{2-6}$ alkenyl optionally substituted with one or more halogen atoms,  $C_{2-6}$ alkynyl optionally substituted with one or more halogen atoms,  $C_{1-6}$ alkyl substituted with cyano or  $-C(=O)R^6$ ,  $C_{1-6}$ alkyloxy,  $C_{1-6}$ alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di( $C_{1-6}$ alkyl)amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio,  $-S(=O)_pR^6$ ,  $-NH-S(=O)_pR^6$ ,  $-C(=O)R^6$ ,  $-NHC(=O)H$ ,  $-C(=O)NHNNH_2$ ,  $-NHC(=O)R^6$ ,  $-C(=NH)R^6$  or aryl;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>1-6</sub>alkyloxy, cyano, nitro, poly-haloC<sub>1-6</sub>alkyl and polyhaloC<sub>1-6</sub>alkyloxy;


5 Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy.

15

The compounds of formula (II) can be prepared according to the methods described in the US patent applications with application number 60/143962 and 60/107792.

20 (III) is an antiviral compound of formula

25



a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein 30 -a¹=a²-a³=a⁴- represents a bivalent radical of formula

- CH=CH-CH=CH- (a-1);
- N=CH-CH=CH- (a-2);
- N=CH-N=CH- (a-3);
- N=CH-CH=N- (a-4);
- 35 -N=N-CH=CH- (a-5);

35 n is 0, 1, 2, 3 or 4; and in case -a¹=a²-a³=a⁴- is (a-1), then n may also be 5;

R¹ is hydrogen, aryl, formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxycarbonyl, C<sub>1-6</sub>alkyl substituted with formyl,


40 C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyloxycarbonyl; and each R² independently is hydroxy, halo, C<sub>1-6</sub>alkyl optionally substituted with cyano or -C(=O)R⁴, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl

optionally substituted with one or more halogen atoms or cyano, C<sub>2-6</sub>alkynyl optionally substituted with one or more halogen atoms or cyano, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkyloxycarbonyl,

45 carboxyl, cyano, nitro, amino, mono- or di(C<sub>1-6</sub>alkyl)amino,

polyhalomethyl, polyhalomethyloxy, polyhalomethylthio,  
 $-S(=O)_pR^4$ ,  $-NH-S(=O)_pR^4$ ,  $-C(=O)R^4$ ,  $-NHC(=O)H$ ,  $-C(=O)NHNH_2$ ,  
 $-NHC(=O)R^4$ ,  $-C(=NH)R^4$  or a radical of formula

5



(c)

wherein each A independently is N, CH or  $CR^4$ ;

B is NH, O, S or  $NR^4$ ;

10 p is 1 or 2; and

$R^4$  is methyl, amino, mono- or dimethylamino or polyhalomethyl;

L is  $C_{4-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{3-7}$ cycloalkyl,  
 whereby each of said aliphatic group may be substituted with

15 one or two substituents independently selected from

\*  $C_{3-7}$ cycloalkyl,

\* indolyl or isoindolyl, each optionally substituted with  
 one, two, three or four substituents each independently  
 selected from halo,  $C_{1-6}$ alkyl, hydroxy,  $C_{1-6}$ alkyloxy,

20 cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and  $C_{1-6}$ alkylcarbonyl,

\* phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl,  
 wherein each of said aromatic rings may optionally be  
 substituted with one, two, three, four or five substituents  
 each independently selected from the substituents

25 defined in  $R^2$ ; or

L is  $-X-R^3$  wherein


$R^3$  is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with two, three, four or five substituents each independently selected from the substituents defined in  $R^2$ ; and

X is  $-NR^{1-}$ ,  $-NH-NH-$ ,  $-N=N-$ ,  $-O-$ ,  $-C(=O)-$ ,  $-CHOH-$ ,  $-S-$ ,  
 $-S(=O)-$  or  $-S(=O)_2-$ ;

35 aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo,  $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl,  $C_{1-6}$ alkyloxy, cyano, nitro, polyhalo $C_{1-6}$ alkyl and polyhalo $C_{1-6}$ alkyloxy.

40 The compounds of formula (III) can be prepared according to the methods described in the US patent application with application number 60/107799.

(IV) is an antiviral compound of formula



10

the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein

R<sup>1</sup> and R<sup>2</sup> are each independently selected from hydrogen; hydroxy;

amino; C<sub>1-6</sub>alkyl; C<sub>1-6</sub>alkyloxy; C<sub>1-6</sub>alkylcarbonyl; C<sub>1-6</sub>alkyl-

15 oxycarbonyl; Ar<sup>1</sup>; mono- or di(C<sub>1-6</sub>alkyl)amino; mono- or di(C<sub>1-6</sub>alkyl)aminocarbonyl; dihydro-2(3H)-furanone; C<sub>1-6</sub>alkyl substituted with one or two substituents each independently selected from amino, imino, aminocarbonyl, aminocarbonyl-

amino, hydroxy, hydroxyC<sub>1-6</sub>alkyloxy, carboxyl, mono- or

20 di(C<sub>1-6</sub>alkyl)amino, C<sub>1-6</sub>alkyloxycarbonyl and thienyl; or R<sup>1</sup> and R<sup>2</sup> taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C<sub>1-6</sub>alkyl)aminoC<sub>1-4</sub>-alkylidene;

R<sup>3</sup> is hydrogen, Ar<sup>1</sup>, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy-

25 carbonyl, C<sub>1-6</sub>alkyl substituted with C<sub>1-6</sub>alkyloxycarbonyl; and R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are each independently selected from hydro-

gen, hydroxy, halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, amino-

carbonyl, nitro, amino, trihalomethyl or trihalomethoxy;

L is C<sub>1-10</sub>alkyl; C<sub>3-10</sub>alkenyl; C<sub>3-10</sub>alkynyl; C<sub>3-7</sub>cycloalkyl; or

30 L is C<sub>1-10</sub>alkyl substituted with one or two substituents independently selected from C<sub>3-7</sub>cycloalkyl; indolyl or indolyl substituted with one, two, three or four substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy,

cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalo-

35 methoxy, C<sub>1-6</sub>alkylcarbonyl; phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalo-

methoxy, C<sub>1-6</sub>alkylcarbonyl; and,

40 Ar<sup>1</sup> is phenyl, or phenyl substituted with one, two or three substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, nitro or trifluoromethyl; with the proviso that compounds (a) to (o)


45

Co. No.	Alk	R <sup>1</sup> /R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	R <sup>8</sup>
a	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	CH <sub>3</sub>	H	H	H	H
b	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	H	H	NO <sub>2</sub>	H	H
5 c	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	C <sub>6</sub> H <sub>5</sub>	H	H	H	H	H
d	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	NO <sub>2</sub>	H	CH <sub>3</sub>	H	H
e	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	H	H	NH <sub>2</sub>	H	H
f	4-(2-methylpropyl)phenylmethyl	H/H	H	H	CF <sub>3</sub>	H	H	H
10 g	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	H	H	Cl	H	H
h	4-(2-methylpropyl)phenylmethyl	H/H	H	H	H	H	H	H
i	3,4-dimethoxyphenylmethyl	H/H	H	H	H	H	H	H
j	2,3-dimethoxyphenylmethyl	H/H	H	H	H	H	H	H
k	3,4-diethoxyphenylmethyl	H/H	H	H	H	H	H	H
15 l	2-(3,5-(1,1-dimethylethyl)-4-hydroxy-phenyl)ethyl	H/H	H	H	H	H	H	H
m	2-(3,5-(1,1-dimethylethyl)-4-hydroxy-phenyl)ethyl	H/H	H	H	t-Bu	OH	t-Bu	H
n	Phenylmethyl	H/H	H	CH <sub>3</sub>	H	H	H	H
o	Phenylmethyl	H/H	H	H	H	H	H	H

20 are not included.


The compounds of formula (IV) can be prepared according to the methods described in EP-A-0834507.

25 (V) is an antifungal compound of formula



the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein  
 n is zero, 1, 2 or 3;  
 40 X is N or CH;  
 each R<sup>1</sup> independently is halo, nitro, cyano, amino, hydroxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy or trifluoromethyl;  
 R<sup>2</sup> is hydrogen; C<sub>3-7</sub>alkenyl; C<sub>3-7</sub>alkynyl, aryl; C<sub>3-7</sub>cycloalkyl; C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkyl substituted with hydroxy, C<sub>1-4</sub>alkyloxy, C<sub>3-7</sub>cycloalkyl or aryl;  
 45 R<sup>3</sup> and R<sup>4</sup> each independently are hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl or aryl; or

R<sup>3</sup> and R<sup>4</sup> taken together form a bivalent radical -R<sup>3</sup>-R<sup>4</sup>- of formula:




10

wherein R<sup>5a</sup>, R<sup>5b</sup>, R<sup>5c</sup>, R<sup>5d</sup> each independently are hydrogen, C<sub>1-6</sub>alkyl or aryl; and aryl is phenyl or phenyl substituted with one, two or three substituents selected from halo, nitro, cyano, amino, hydroxy, 15 C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy or trifluoromethyl.

The compounds of formula (V) can be prepared according to the methods described in WO 99/02523.

20 (VI) is an apolipoprotein-B synthesis inhibitor of formula



30

the N-oxides, the stereochemically isomeric forms thereof, and the pharmaceutically acceptable acid addition salts, wherein A and B taken together form a bivalent radical of formula :

35

-N=CH- (a),  
 -CH=N- (b),  
 -CH<sub>2</sub>-CH<sub>2</sub>- (c),  
 -CH=CH- (d),  
 -C(=O)-CH<sub>2</sub>- (e),  
 -CH<sub>2</sub>-C(=O)- (f),

40 in the bivalent radicals of formula (a) and (b) the hydrogen atom may be replaced by C<sub>1-6</sub>alkyl; in the bivalent radicals of formula (c), (d), (e), (f), one or two hydrogen atoms may be replaced by C<sub>1-6</sub>alkyl;

R<sup>1</sup> is hydrogen, C<sub>1-6</sub>alkyl or halo;

45 R<sup>2</sup> is hydrogen or halo;

R<sup>3</sup> is hydrogen; C<sub>1-8</sub>alkyl; C<sub>3-6</sub>cycloalkyl; or C<sub>1-8</sub>alkyl substituted with hydroxy, oxo, C<sub>3-6</sub>cycloalkyl or aryl;

Het is a heterocycle selected from the group consisting of pyridine; pyridine substituted with one or two substituents selected from C<sub>1</sub>-6alkyl, hydroxy, C<sub>1</sub>-6alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1</sub>-6alkyl)amino or aryl; pyrimidine; 5 pyrimidine substituted with one or two substituents selected from C<sub>1</sub>-6alkyl, hydroxy, C<sub>1</sub>-6alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1</sub>-6alkyl)-amino or aryl; tetrazole; tetrazole substituted with C<sub>1</sub>-6alkyl or aryl; triazole; triazole substituted with one or two substituents selected from C<sub>1</sub>-6alkyl, 10 hydroxy, C<sub>1</sub>-6alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1</sub>-6alkyl)-amino; thiadiazole; thiadiazole substituted with one or two substituents selected from C<sub>1</sub>-6alkyl, hydroxy, C<sub>1</sub>-6alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1</sub>-6alkyl)-amino; oxadiazole substituted with one or two substituents 15 selected from C<sub>1</sub>-6alkyl, hydroxy, C<sub>1</sub>-6alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1</sub>-6alkyl)amino; imidazole; imidazole substituted with one or two substituents selected from C<sub>1</sub>-6alkyl, hydroxy, C<sub>1</sub>-6alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1</sub>-6alkyl)amino; thiazole; thiazole substituted with one or 20 two substituents selected from C<sub>1</sub>-6alkyl, hydroxy, C<sub>1</sub>-6alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1</sub>-6alkyl)amino; oxazole; oxazole substituted with one or two substituents selected from C<sub>1</sub>-6alkyl, hydroxy, C<sub>1</sub>-6alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1</sub>-6alkyl)amino; 25 aryl is phenyl or phenyl substituted with C<sub>1</sub>-6alkyl or halo.

The heterocyclic radical "Het" is bound to the sulfur atom via a carbon atom.

30 The compounds of formula (VI) can be prepared according to the methods described in WO 96/13499.

The particles comprise the compounds of formula (I) to (VI) as a solid dispersion in a polymeric matrix, wherein the polymeric matrix is consisting of a homo- or copolymer of N-vinyl-35 pyrrolidone. Furthermore, the invention concerns a process for manufacturing of such particles and pharmaceutical dosage forms comprising such particles.

40 The compounds of formula (I) to (VI) contained in the particles show poor bio-availability.

In order to improve the dissolution characteristics the compounds are dispersed in a polymeric matrix, preferably by using a melt-45 extrusion process.

EP-A 0 240 904 discloses a method for producing solid pharmaceutical forms by extrusion of polymer melts which contain active substances, using as polymers homo- or copolymers of N-vinyl-pyrrolidone.

5

EP-B 0 580 860 discloses a method for producing solid dispersions of drug substances in a polymeric matrix using a twin screw extruder.

10 It is an object of the present invention to provide rate-controlled pharmaceutical forms containing the aforementioned compounds.

We have found that this object is achieved by the particles

15 defined at the outset.

Preferred compounds according to the invention are:

4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

20 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile;

4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;

4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;

25 4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-amino]benzonitrile;

4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

30 4-[[5-bromo-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;

4-[[4-amino-5-chloro-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile;

4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile;

35 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-1,3,5-triazin-2-yl]amino]benzonitrile;

4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-1,3,5-triazin-2-yl]-amino]benzonitrile;

40 4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-1,3,5-triazin-2-yl]amino]benzonitrile;

1-[4-[4-[[4-(2,4-difluorophenyl)-4-(1H-1,2,4-triazol-1-yl-methyl)-1,3-dioxolan-2-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-3-(1-methylethyl)-2-imidazolidinone;

45

(--)[2S-[2alpha,4alpha(S\*)]]-4-[4-[4-[[2-(4-chlorophenyl)-2-  
[(4-methyl-4H-1,2,4-triazol-3-yl)thio]methyl]-1,3-dioxolan-4-yl]  
methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methyl-  
propyl)-3H-1,2,4-triazol-3-one,

5 a N-oxide, a pharmaceutically acceptable addition salt or a  
stereochemically isomeric form thereof.

According to the present invention the term "rate-controlled"  
means that depending on the composition of the matrix the  
10 particles can show instant release of the active ingredient or  
modified release (sustained release).

The compounds according to the invention are homogeneously  
dispersed in a polymer matrix consisting of a homopolymer of  
15 N-vinylpyrrolidone or, preferably, a copolymer of N-vinyl-  
pyrrolidone. A preferred copolymer is a copolymer of N-vinyl-  
pyrrolidone and vinyl acetate, especially a copolymer obtained  
from 60% b.w. of NVP and 40% b.w. of vinylacetate.

20 The polymers show Fikentscher K values of from 17 to 90,  
preferably a K value of 30 (for the definition of the K value  
see "H. Fikentscher, Cellulose-Chemie" (1932), 58-64 and 71-74).

The polymeric matrix component is used in amounts of from 40 to  
25 70, preferably of from 50 to 65% b.w. of the total weight of the  
particles.

In a preferred embodiment of the invention the polymeric matrix  
further comprises a surfactant, preferably a surfactant with  
30 a HLB-value of 10-18 (HLB: Hydrophilic Lipophilic Balance).  
Especially preferred surfactants are selected from the group  
consisting of low molecular weight polyoxyethylene polyoxy-  
propylene block copolymers with a mean molecular weight of  
1000 to 6000 g/mol, and hydrogenated castor oil which can be  
35 modified with polyethylene glycol.

The amounts of surfactants used lies in the range of up to 20%  
b.w., preferably 5 to 15% b.w., of the particles.

40 In another preferred embodiment the matrix further comprises an  
organic carboxylic acid in amounts of up to 5% b.w. of the  
particles.

In another preferred embodiment of the invention the polymeric  
matrix further comprises hydroxypropyl methyl cellulose in  
45 amounts of up to 25% b.w., preferably from 5 to 10% b.w..

The particles of the present invention are prepared as solid dispersions of the active compounds in a polymeric matrix. The term "solid dispersion" is well known in the art and means a dispersion consisting of solid components. Preferably solid dispersions are in the form of solid solutions wherein the active ingredients are molecularly dispersed in the polymeric matrix.

Such solid dispersion is preferably obtained by forming a homogeneous mixture of the components in the form of a melt, 10 extruding said melt and shaping of the extrudate. The melting is effected by the input of thermal and/or mechanic energy.

Depending on the composition of the matrix, the melting takes place in the range of from 40°C to 190°C, preferably 50 to 150°C.

15 The suitable temperature range depends on the glass transition temperature of the polymer component, the properties of the active ingredients and further additives. The optimal temperature range can be established by a few simple tests.

20 The mixing of the active substances with the polymer and additional components of the matrix can take place before or after the melting of the polymer. Preferably the process is solvent-free which means that no additional organic solvents or water are added.

25 The plastification and melting preferably can take place in an extruder, a kneader or a mixing reactor, preferably in an extruder having one or more screws which may rotate in the same direction or opposite directions, especially in a twin screw 30 extruder. The latter can be operated with or without kneading elements, but use of kneading elements is preferred because mixing is better.

The still plastic material is extruded through a die or a breaker 35 plate and then shaped into particles. This may be effected by milling and subsequent sieving the cooled extrudate. The preferred particle size for instant release forms lies in the range of from 0.5 to 1.5 mm.

40 The particles, optionally together with conventional pharmaceutically acceptable excipients, may be further processed to conventional pharmaceutical dosage forms such as tablets, pastilles, suppositories, or be packed in capsules.

45 It is possible and particularly advantageous to produce pharmaceutical forms with rate-controlled release and improved dissolution rates of the active ingredients. This was not to be

14

expected in view of the low solubility of the active ingredients in aqueous media.

**Examples**

5

**General method**

Powder mixes of the components were melt kneaded at 145°C for 5 min.. After cooling the solidified melts were ground and 10 sieved. The sieve fraction 0.5-1.5 mm was used for the dissolution tests.

The composition of the individual powder mixes is listed in Table 1.

15

**Table 1**

Example No.	1	2	3	4	5	.6
Active ingredient <sup>1)</sup>	30	30	30	30	30	40
VP-VAC-copolymer <sup>2)</sup>	65	55	55	60	55	47,1
Surfactant <sup>3)</sup>	5	15		5	5	4,3
Citric acid				5		
HPMC					10	8,6
Surfactant <sup>4)</sup>			15			

25 1) 4-[[4-[2,4,6-trimethylphenyl]amino]-2-pyrimidinyl]amino]-benzonitrile

2) Kollidon® VA64, VP/VAC = 60/40, BASF Aktiengesellschaft

3) PEG-n-hydrogenated Castoroil

4) polyoxyethylene polyoxypropylene blockcopolymer, mean mol.

30 weight 4000 g/mol

The dissolution tests were carried out according to USP XXIII, paddle model, pH no change test, 0.1 M HCl, at 37°C, 100 rpm

35

40

45

The results are listed in Table 2.

Table 2: Dissolution Rates of particles according to examples 1-6

5

time [min]	Dissolution [%]				time [min]	Dissolution [%]	
	Ex. 1 (IR)	Ex. 2 (IR)	Ex. 3 (IR)	Ex. 4 (IR)		Ex. 5 (SR)	Ex. 6 (SR)
10	5	53	65	58	57	1	
	10	73	86	88	82	2	
	15	77	91	95	89	3	
	20	81	91	96	93	4	
15	30	87	94	99	94	6	
	60	92	93	96	94	8	96
	120	93	94	97	95		95
	IR: Instant Release					SR: Sustained Release	

20 DSC-Measurements were performed with the formulations according to examples 1 to 6 in open pans (air) at temperatures of from 20 → 250°C, with a heating rate of 10°C per minute. There is no indication of crystalline drug substance in the solid dispersions.

25

30

35


40

45

## Claims

1. Rate-controlled release particles, comprising a compound of  
 5 formula I

10



a N-oxide, a pharmaceutically acceptable addition salt or a  
 stereoisomeric form thereof, wherein

15

Y is CR<sup>5</sup> or N;

A is CH, CR<sup>4</sup> or N;

n is 0, 1, 2, 3 or 4;

Q is -NR<sup>1</sup>R<sup>2</sup> or when Y is CR<sup>5</sup> then Q may also be hydrogen;

20 R<sup>1</sup> and R<sup>2</sup> are each independently selected from hydrogen,  
 hydroxy, C<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkyloxy, C<sub>1-12</sub>alkylcarbonyl,  
 C<sub>1-12</sub>alkyloxycarbonyl, aryl, amino, mono- or  
 di(C<sub>1-12</sub>alkyl)-amino, mono- or di(C<sub>1-12</sub>alkyl)aminocarbonyl  
 wherein each of the aforementioned C<sub>1-12</sub>alkyl groups may  
 25 optionally and each individually be substituted with one  
 or two substituents each independently selected from  
 hydroxy, C<sub>1-6</sub>alkyloxy, hydroxy-C<sub>1-6</sub>alkyloxy, carboxyl,  
 C<sub>1-6</sub>alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl,  
 aminocarbonylamino, mono- or di(C<sub>1-6</sub>alkyl)amino, aryl and  
 30 Het; or

R<sup>1</sup> and R<sup>2</sup> taken together may form pyrrolidinyl, piperidinyl,  
 morpholinyl, azido or mono- or di(C<sub>1-12</sub>alkyl)aminoC<sub>1-4</sub>-  
 alkylidene;

35 R<sup>3</sup> is hydrogen, aryl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl-  
 oxycarbonyl, C<sub>1-6</sub>alkyl substituted with C<sub>1-6</sub>alkyloxy-  
 carbonyl; and

40 each R<sup>4</sup> independently is hydroxy, halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl-  
 oxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl,  
 trihalomethoxy, or when Y is CR<sup>5</sup> then R<sup>4</sup> may also  
 represent C<sub>1-6</sub>alkyl substituted with cyano or amino-  
 carbonyl;

R<sup>5</sup> is hydrogen or C<sub>1-4</sub>alkyl;

L is -X<sup>1</sup>-R<sup>6</sup> or -X<sup>2</sup>-Alk-R<sup>7</sup> wherein

45 R<sup>6</sup> and R<sup>7</sup> each independently are phenyl or phenyl substi-  
 tuted with one, two, three, four or five substituents  
 each independently selected from halo, hydroxy,

## 17

*C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl-oxycarbonyl, formyl, cyano, nitro, amino, and trifluoromethyl; or when Y is CR<sup>5</sup> then R<sup>6</sup> and R<sup>7</sup> may also be selected from phenyl substituted with one, two, three, four or five substituents each independently selected from aminocarbonyl, trihalomethyloxy and trihalomethyl; or when Y is N then R<sup>6</sup> and R<sup>7</sup> may also be selected from indanyl or indolyl, each of said indanyl or indolyl may be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyloxycarbonyl, formyl, cyano, nitro, amino, and trifluoromethyl;*

*X<sup>1</sup> and X<sup>2</sup> are each independently -NR<sup>3</sup>-, -NH-NH-, -N=N-, -O-, -S-, -S(=O)- or -S(=O)<sub>2</sub>-;*


*Alk is C<sub>1-4</sub>alkanediyl; or*

*when Y is CR<sup>5</sup> then L may also be selected from C<sub>1-10</sub>alkyl, C<sub>3-10</sub>alkenyl, C<sub>3-10</sub>alkynyl, C<sub>3-7</sub>cycloalkyl, or C<sub>1-10</sub>alkyl substituted with one or two substituents independently selected from C<sub>3-7</sub>cycloalkyl, indanyl, indolyl and phenyl, wherein said phenyl, indanyl and indolyl may be substituted with one, two, three, four or where possible five substituents each independently selected from halo, hydroxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, C<sub>1-6</sub>alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl, trihalomethyloxy and C<sub>1-6</sub>alkylcarbonyl;*

*aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, nitro and trifluoromethyl;*

*Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thieryl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy,*

or a compound of formula



10 the *N*-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein

-b¹=b²-C(R²a)=b³-b⁴= represents a bivalent radical of formula

-CH=CH-C(R²a)=CH-CH= (b-1);

15 -N=CH-C(R²a)=CH-CH= (b-2);

-CH=N-C(R²a)=CH-CH= (b-3);

-N=CH-C(R²a)=N-CH= (b-4);

-N=CH-C(R²a)=CH-N= (b-5);

-CH=N-C(R²a)=N-CH= (b-6);

20 -N=N-C(R²a)=CH-CH= (b-7);


q is 0, 1, 2; or where possible q is 3 or 4;

R¹ is hydrogen, aryl, formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxycarbonyl, C<sub>1-6</sub>alkyl substituted with formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyloxycarbonyl;

25 R²a is cyano, aminocarbonyl, mono- or di(methyl)amino- carbonyl, C<sub>1-6</sub>alkyl substituted with cyano, amino- carbonyl or mono- or di(methyl)aminocarbonyl, C<sub>2-6</sub>alkenyl substituted with cyano, or C<sub>2-6</sub>alkynyl substituted with cyano;

30 each R² independently is hydroxy, halo, C<sub>1-6</sub>alkyl optionally substituted with cyano or -C(=O)R⁶, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl optionally substituted with one or more halogen atoms or cyano, C<sub>2-6</sub>alkynyl optionally substituted with one or more halogen atoms or cyano, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C<sub>1-6</sub>alkyl)amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, -S(=O)pR⁶, -NH-S(=O)pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH<sub>2</sub>, -NHC(=O)R⁶, -C(=NH)R⁶ or a radical of formula

40



(c)

45

## 19

wherein each A independently is N, CH or CR<sup>6</sup>;

B is NH, O, S or NR<sup>6</sup>;

p is 1 or 2; and

R<sup>6</sup> is methyl, amino, mono- or dimethylamino or polyhalomethyl;

5 L is C<sub>1-10</sub>alkyl, C<sub>2-10</sub>alkenyl, C<sub>2-10</sub>alkynyl, C<sub>3-7</sub>cycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from

\* C<sub>3-7</sub>cycloalkyl,

10 \* indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C<sub>1-6</sub>alkyl-carbonyl,

15 \* phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected

20 from the substituents defined in R<sup>2</sup>; or

L is -X-R<sup>3</sup> wherein

R<sup>3</sup> is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R<sup>2</sup>; and

25 X is -NR<sup>1</sup>-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -S(=O)<sub>2</sub>-;

Q represents hydrogen, C<sub>1-6</sub>alkyl, halo, polyhaloC<sub>1-6</sub>alkyl or

30 -NR<sup>4</sup>R<sup>5</sup>; and

R<sup>4</sup> and R<sup>5</sup> are each independently selected from hydrogen, hydroxy, C<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkyloxy, C<sub>1-12</sub>alkylcarbonyl, C<sub>1-12</sub>alkyloxycarbonyl, aryl, amino, mono- or di(C<sub>1-12</sub>alkyl)amino, mono- or di(C<sub>1-12</sub>alkyl)aminocarbonyl

35 wherein each of the aforementioned C<sub>1-12</sub>alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C<sub>1-6</sub>alkyloxy, hydroxyC<sub>1-6</sub>alkyloxy, carboxyl, C<sub>1-6</sub>alkyloxycarbonyl, cyano, amino, imino, mono- or di(C<sub>1-6</sub>alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)<sub>p</sub>R<sup>6</sup>, -NH-S(=O)<sub>p</sub>R<sup>6</sup>, -C(=O)R<sup>6</sup>, -NHC(=O)H, -C(=O)NHNH<sub>2</sub>, -NHC(=O)R<sup>6</sup>, -C(=NH)R<sup>6</sup>, aryl and Het; or

40 R<sup>4</sup> and R<sup>5</sup> taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C<sub>1-12</sub>alkyl)aminoC<sub>1-4</sub>-alkylidene;

45

## 20


Y represents hydroxy, halo, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl optionally substituted with one or more halogen atoms, C<sub>2-6</sub>alkynyl optionally substituted with one or more halogen atoms, C<sub>1-6</sub>alkyl substituted with cyano or -C(=O)R<sup>6</sup>, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C<sub>1-6</sub>alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)<sub>p</sub>R<sup>6</sup>, -NH-S(=O)<sub>p</sub>R<sup>6</sup>, -C(=O)R<sup>6</sup>, -NHC(=O)H, -C(=O)NHNH<sub>2</sub>, -NHC(=O)R<sup>6</sup>, -C(=NH)R<sup>6</sup> or aryl;

10 aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>1-6</sub>alkyloxy, cyano, nitro, polyhaloC<sub>1-6</sub>alkyl and polyhaloC<sub>1-6</sub>alkyloxy;

15 Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy,

20

25 or a compound of formula



35 a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein

-a¹=a²=a³=a⁴- represents a bivalent radical of formula


40

-CH=CH-CH=CH- (a-1);  
 -N=CH-CH=CH- (a-2);  
 -N=CH-N=CH- (a-3);  
 -N=CH-CH=N- (a-4);  
 -N=N-CH=CH- (a-5);

n is 0, 1, 2, 3 or 4; and in case -a¹=a²=a³=a⁴- is (a-1), then n may also be 5;

45 R¹ is hydrogen, aryl, formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxycarbonyl, C<sub>1-6</sub>alkyl substituted with formyl, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyloxycarbonyl; and

each R<sup>2</sup> independently is hydroxy, halo, C<sub>1-6</sub>alkyl optionally substituted with cyano or -C(=O)R<sup>4</sup>, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl optionally substituted with one or more halogen atoms or cyano, C<sub>2-6</sub>alkynyl optionally substituted with one or more halogen atoms or cyano, C<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C<sub>1-6</sub>alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)<sub>p</sub>R<sup>4</sup>, -NH-S(=O)<sub>p</sub>R<sup>4</sup>, -C(=O)R<sup>4</sup>, -NHC(=O)H, -C(=O)NHNH<sub>2</sub>, -NHC(=O)R<sup>4</sup>, -C(=NH)R<sup>4</sup> or a radical of formula



(c)

wherein each A independently is N, CH or CR<sup>4</sup>;  
 B is NH, O, S or NR<sup>4</sup>;  
 p is 1 or 2; and  
 R<sup>4</sup> is methyl, amino, mono- or dimethylamino or polyhalomethyl;

20 L is C<sub>4-10</sub>alkyl, C<sub>2-10</sub>alkenyl, C<sub>2-10</sub>alkynyl, C<sub>3-7</sub>cycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from

- \* C<sub>3-7</sub>cycloalkyl,
- \* indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C<sub>1-6</sub>alkylcarbonyl,


25 \* phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R<sup>2</sup>; or

30 35 L is -X-R<sup>3</sup> wherein R<sup>3</sup> is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with two, three, four or five substituents each independently selected from the substituents defined in R<sup>2</sup>; and

40 45 X is -NR<sup>1</sup>-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -S(=O)<sub>2</sub>-;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>1-6</sub>alkyloxy, cyano, nitro, polyhaloC<sub>1-6</sub>alkyl and polyhaloC<sub>1-6</sub>alkyloxy,

or a compound of formula



10

the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein R<sup>1</sup> and R<sup>2</sup> are each independently selected from hydrogen;

15

hydroxy; amino; C<sub>1-6</sub>alkyl; C<sub>1-6</sub>alkyloxy; C<sub>1-6</sub>alkylcarbonyl; C<sub>1-6</sub>alkyloxycarbonyl; Ar<sup>1</sup>; mono- or di(C<sub>1-6</sub>alkyl)amino; mono- or di(C<sub>1-6</sub>alkyl)aminocarbonyl; dihydro-2(3H)-furanone; C<sub>1-6</sub>alkyl substituted with one or two substituents each independently selected from amino, imino, aminocarbonyl, aminocarbonylamino, hydroxy, hydroxyC<sub>1-6</sub>alkyloxy, carboxyl, mono- or di(C<sub>1-6</sub>alkyl)amino, C<sub>1-6</sub>alkyloxy-carbonyl and thienyl; or

20

R<sup>1</sup> and R<sup>2</sup> taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C<sub>1-6</sub>alkyl)aminoC<sub>1-4</sub>-alkylidene;

25

R<sup>3</sup> is hydrogen, Ar<sup>1</sup>, C<sub>1-6</sub>alkylcarbonyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy-carbonyl, C<sub>1-6</sub>alkyl substituted with C<sub>1-6</sub>alkyloxycarbonyl; and

30

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are each independently selected from hydrogen, hydroxy, halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalome-thyloxy;

L is C<sub>1-10</sub>alkyl; C<sub>3-10</sub>alkenyl; C<sub>3-10</sub>alkynyl; C<sub>3-7</sub>cycloalkyl; or

35

L is C<sub>1-10</sub>alkyl substituted with one or two substituents independently selected from C<sub>3-7</sub>cycloalkyl; indolyl or indolyl substituted with one, two, three or four substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, C<sub>1-6</sub>alkylcarbonyl; phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, C<sub>1-6</sub>alkylcarbonyl; and,

40

45

Ar<sup>1</sup> is phenyl, or phenyl substituted with one, two or three substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, nitro or trifluoromethyl; with the proviso that compounds (a) to (o)


5	Co. No.	Alk	R <sup>1</sup> /R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	R <sup>8</sup>
	a	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	CH <sub>3</sub>	H	H	H	H
	b	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	H	H	NO <sub>2</sub>	H	H
	c	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	C <sub>6</sub> H <sub>5</sub>	H	H	H	H	H
10	d	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	NO <sub>2</sub>	H	CH <sub>3</sub>	H	H
	e	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	H	H	NH <sub>2</sub>	H	H
	f	4-(2-methylpropyl)phenylmethyl	H/H	H	H	CF <sub>3</sub>	H	H	H
	g	1-(4-(2-methylpropyl)phenyl)ethyl	H/H	H	H	H	Cl	H	H
	h	4-(2-methylpropyl)phenylmethyl	H/H	H	H	H	H	H	H
15	i	3,4-dimethoxyphenylmethyl	H/H	H	H	H	H	H	H
	j	2,3-dimethoxyphenylmethyl	H/H	H	H	H	H	H	H
	k	3,4-diethoxyphenylmethyl	H/H	H	H	H	H	H	H
	l	2-(3,5-(1,1-dimethylethyl)-4-hydroxy-phenyl)ethyl	H/H	H	H	H	H	H	H
20	m	2-(3,5-(1,1-dimethylethyl)-4-hydroxy-phenyl)ethyl	H/H	H	H	t-Bu	OH	t-Bu	H
	n	Phenylmethyl	H/H	H	CH <sub>3</sub>	H	H	H	H
	o	Phenylmethyl	H/H	H	H	H	H	H	H

are not included,

25

or a compound of formula

30



35

the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof,  
40 wherein

n is zero, 1, 2 or 3;

X is N or CH;

each R<sup>1</sup> independently is halo, nitro, cyano, amino, hydroxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxy or trifluoromethyl;

45 R<sup>2</sup> is hydrogen; C<sub>3-7</sub>alkenyl; C<sub>3-7</sub>alkynyl, aryl; C<sub>3-7</sub>cycloalkyl; C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkyl substituted with hydroxy, C<sub>1-4</sub>alkyloxy, C<sub>3-7</sub>cycloalkyl or aryl;


$R^3$  and  $R^4$  each independently are hydrogen,  $C_{1-6}$ alkyl,

$C_{3-7}$ cycloalkyl or aryl; or

$R^3$  and  $R^4$  taken together form a bivalent radical  $-R^3-R^4-$  of formula:

5

10



(b)

(c)

(d)

(e)

wherein  $R^{5a}$ ,  $R^{5b}$ ,  $R^{5c}$ ,  $R^{5d}$  each independently are hydrogen,  $C_{1-6}$ alkyl or aryl; and


15

aryl is phenyl or phenyl substituted with one, two or three substituents selected from halo, nitro, cyano, amino, hydroxy,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkyloxy or trifluoromethyl,

or a compound of formula

20

25



30

the  $N$ -oxides, the stereochemically isomeric forms thereof, and the pharmaceutically acceptable acid addition salts, wherein A and B taken together form a bivalent radical of formula :

35

$-N=CH-$  (a),

$-CH=N-$  (b),

$-CH_2-CH_2-$  (c),

$-CH=CH-$  (d),

$-C(=O)-CH_2-$  (e),

$-CH_2-C(=O)-$  (f),

40

in the bivalent radicals of formula (a) and (b) the hydrogen atom may be replaced by  $C_{1-6}$ alkyl; in the bivalent radicals of formula (c), (d), (e), (f), one or two hydrogen atoms may be replaced by  $C_{1-6}$ alkyl;

$R^1$  is hydrogen,  $C_{1-6}$ alkyl or halo;

45

$R^2$  is hydrogen or halo;

$R^3$  is hydrogen;  $C_{1-8}$ alkyl;  $C_{3-6}$ cycloalkyl; or  $C_{1-8}$ alkyl substituted with hydroxy, oxo,  $C_{3-6}$ cycloalkyl or aryl;

Het is a heterocycle selected from the group consisting of pyridine; pyridine substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino or aryl; pyrimidine; pyrimidine substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)-amino or aryl; tetrazole; tetrazole substituted with C<sub>1-6</sub>alkyl or aryl; triazole; triazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)-amino; thiadiazole; thiadiazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)-amino; oxadiazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; imidazole; imidazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; thiazole; thiazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; oxazole; oxazole substituted with one or two substituents selected from C<sub>1-6</sub>alkyl, hydroxy, C<sub>1-6</sub>alkyloxy, trihalomethyl, amino, mono- or di(C<sub>1-6</sub>alkyl)amino; aryl is phenyl or phenyl substituted with C<sub>1-6</sub>alkyl or halo, and the heterocyclic radical "Het" is bound to the sulfur atom via a carbon atom,

as a solid dispersion in a polymeric matrix, wherein the polymeric matrix is consisting of a homo- or copolymer of N-vinylpyrrolidone.

35 2. Particles according to claim 1, wherein the copolymer of N-vinylpyrrolidone is a copolymer with vinyl acetate.

3. Particles according to claim 1 or 2, further comprising a surfactant.

40 4. Particles according to claim 3, wherein the surfactant is a PEG-n-hydrogenated castor oil.

5. Particles according to any of the claims 1 to 3, wherein the surfactant is a low molecular weight polyoxyethylene polyoxypropylene block copolymer.

6. Particles according to any of the claims 1 to 3, further comprising citric acid in amounts of up to 5 % b.w.
7. Particles according to any of the claims 1 to 6, wherein the 5 homo- or copolymer of N-vinylpyrrolidone is used in amounts of from 40 to 70 % b.w. of the total weight of the dosage form.
8. Particles according to claim 7, wherein the homo- or copolymer of N-vinylpyrrolidone is used in amounts of from 50 to 65 10 % b.w..
9. Particles according to any of the claims 1 to 8, wherein the controlled release is an instant release of the drug.
- 15 10. Particles according to any of the claims 1 to 8, wherein the controlled release is a sustained release.
11. Particles according to claim 10, further comprising hydroxy- 20 propyl methyl cellulose in amounts of from 5 to 10 % b.w..
12. Particles according to any of the claims 1 to 11, obtained by forming a homogeneous mixture of the components in the form of a melt, extruding said mixture and shaping of the extrudate.
- 25 13. Particles according to any of the claims 1 to 11, comprising a compound selected from the group consisting of 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]-benzonitrile;
14. 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- 30 benzonitrile;
15. 4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;
16. 4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;
17. 4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-amino]benzonitrile;
18. 4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
19. 4-[[5-bromo-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;
20. 4-[[4-amino-5-chloro-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile;
21. 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile;

27

4-[[4-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]-amino]benzonitrile;  
4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-1,3,5-triazin-2-yl]amino]benzonitrile;  
5 4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-1,3,5-triazin-2-yl]amino]benzonitrile;  
1-[4-[4-[[4-(2,4-difluorophenyl)-4-(1H-1,2,4-triazol-1-yl-methyl)-1,3-dioxolan-2-yl]methoxy]phenyl]-1-piperazinyl]-phenyl]-3-(1-methylethyl)-2-imidazolidinone;  
10 (-)-[2S-[2alpha,4alpha(S\*)]]-4-[4-[4-[[2-(4-chlorophenyl)-2-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methyl-propyl)-3H-1,2,4-triazol-3-one,  
15 a N-oxide, a pharmaceutically acceptable addition salt or a stereoisomerically isomeric form thereof.

14. Pharmaceutical dosage form, comprising particles according to any of the preceding claims.

20 15. Pharmaceutical dosage forms according to claim 13, further comprising one or more pharmaceutically acceptable excipients.

25

30

35

40

45

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number  
WO 01/23362 A3

(51) International Patent Classification<sup>7</sup>: C07D 239/48, 251/18, 239/50, 403/12, 521/00, 405/14, A61K 31/505, A61P 35/00, A61K 9/16, 9/14

(74) Agent: KINZEBACH, Werner; Ludwigplatz 4, 67059 Ludwigshafen (DE).

(21) International Application Number: PCT/EP00/09149

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date:  
19 September 2000 (19.09.2000)

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(25) Filing Language: English

Published:  
— with international search report

(26) Publication Language: English

(88) Date of publication of the international search report:  
6 December 2001

(30) Priority Data:  
199 45 982.7 24 September 1999 (24.09.1999) DE


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): KNOLL

AKTIENGESELLSCHAFT [DE/DE]; 67061 Ludwigshafen (DE).


(72) Inventors; and

(75) Inventors/Applicants (for US only): HANTKE, Thomas [DE/DE]; Landauerstrasse 5, 67067 Ludwigshafen (DE). REHBOCK, Bettina [DE/DE]; Wasgauring 28, 67125 Dannstadt (DE). ROSENBERG, Jörg [DE/DE]; Bruchstrasse 29, 67158 Ellerstadt (DE). BREITENBACH, Jörg [DE/DE]; Hans-Sachs-Ring 95A, 68199 Mannheim (DE).



(54) Title: RATE-CONTROLLED PARTICLES

WO 01/23362 A3



(57) Abstract: Rate-controlled particles, comprising compounds of formula (I) as a solid dispersion.

# INTERNATIONAL SEARCH REPORT

Internet Application No

PCT/EP 00/09149

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/48 C07D251/18 C07D239/50 C07D403/12 C07D521/00  
C07D405/14 A61K31/505 A61P35/00 A61K9/16 A61K9/14

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 872 233 A (JANSSEN) 21 October 1998 (1998-10-21)  page 1 -page 11 ---	1-5, 10-12, 14,15
Y	EP 0 834 507 A (JANSSEN) 8 April 1998 (1998-04-08) cited in the application page 1 -page 5; claims; tables 2-5 ---	1-5, 10-12, 14,15
Y	WO 99 02523 A (JANSSEN) 21 January 1999 (1999-01-21) cited in the application the whole document ---	1-5, 10-12, 14,15  -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

17 May 2001

31/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

## INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/EP 00/09149

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 13499 A (JANSSEN) 9 May 1996 (1996-05-09) cited in the application page 0; claims; tables 10,11 ---	1-5, 10-12, 14,15
Y	US 5 880 130 A (ANDREW PETER THOMAS) 9 March 1999 (1999-03-09)  column 37, line 10 -column 50 ---	1-5, 10-12, 14,15
Y	WO 97 19065 A (CELLTECH) 29 May 1997 (1997-05-29)  page 1 -page 15; claims ---	1-5, 10-12, 14,15
Y	WO 98 41512 A (CELLTECH) 24 September 1998 (1998-09-24)  page 1 -page 18; claims ---	1-5, 10-12, 14,15
Y	WO 91 18887 A (SMITH-KLINE) 12 December 1991 (1991-12-12)  page 1 -page 10; claims ---	1-5, 10-12, 14,15
P,Y	WO 99 50256 A (JANSSEN) 7 October 1999 (1999-10-07)  the whole document ---	1-5, 10-12, 14,15
P,Y	WO 00 27828 A (JANSSEN) 18 May 2000 (2000-05-18) cited in the application page 15; claims ---	1-5, 10-12, 14,15
P,Y	EP 0 945 443 A (JANSSEN) 29 September 1999 (1999-09-29)  the whole document -----	1-5, 10-12, 14,15

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Internal Application No

PCT/EP 00/09149

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 872233	A	21-10-1998	NONE	
EP 834507	A	08-04-1998	AU 3926697 A BR 9704937 A CA 2216486 A CN 1180698 A CZ 9702993 A HR 970526 A HU 9701596 A JP 10114759 A NO 974368 A PL 322369 A SG 53075 A SK 131997 A TR 9701070 A TW 411335 B ZA 9708766 A	09-04-1998 06-06-2000 01-04-1998 06-05-1998 11-11-1998 31-10-1998 28-06-1999 06-05-1998 02-04-1998 14-04-1998 28-09-1998 11-06-1999 21-04-1998 11-11-2000 30-03-1999
WO 9902523	A	21-01-1999	AU 8857598 A AU 8857698 A BG 103934 A BR 9811676 A BR 9811679 A CN 1262675 T CN 1262684 T WO 9902496 A EP 1000029 A EP 1068200 A HR 20000004 A HR 20000007 A HU 0003078 A JP 2000515560 T NO 20000093 A PL 337648 A SK 182999 A SK 184199 A TR 200000020 T	08-02-1999 08-02-1999 30-11-2000 19-09-2000 19-09-2000 09-08-2000 09-08-2000 21-01-1999 17-05-2000 17-01-2001 31-12-2000 31-12-2000 29-01-2001 21-11-2000 10-03-2000 28-08-2000 14-08-2000 11-07-2000 21-09-2000
WO 9613499	A	09-05-1996	AP 779 A AT 198889 T AU 697744 B AU 3868095 A BG 101402 A BR 9509436 A CZ 9701198 A DE 69519995 D EP 0788496 A FI 971784 A HR 950532 A HU 77360 A IL 115771 A JP 3025907 B JP 9511759 T KR 227231 B NO 971895 A NZ 295353 A PL 319905 A RU 2144032 C	03-11-1999 15-02-2001 15-10-1998 23-05-1996 31-10-1997 06-01-1998 18-03-1998 01-03-2001 13-08-1997 25-04-1997 31-08-1997 30-03-1998 29-02-2000 27-03-2000 25-11-1997 01-11-1999 24-04-1997 26-08-1998 01-09-1997 10-01-2000

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Internal ref. no.: Application No

PCT/EP 00/09149

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9613499 A		SK 50797 A			08-04-1998
		TR 960337 A			21-06-1996
		US 5521186 A			28-05-1996
		US 5929075 A			27-07-1999
		ZA 9509084 A			29-04-1997
US 5880130 A	09-03-1999	AU 1194895 A			27-06-1995
		EP 0733045 A			25-09-1996
		WO 9515952 A			15-06-1995
		JP 9506363 T			24-06-1997
		ZA 9409546 A			23-06-1995
WO 9719065 A	29-05-1997	AU 7631496 A			11-06-1997
		EP 0862560 A			09-09-1998
		US 5958935 A			28-09-1999
WO 9841512 A	24-09-1998	AU 6411698 A			12-10-1998
		EP 0970056 A			12-01-2000
		US 6048866 A			11-04-2000
WO 9118887 A	12-12-1991	AU 7971691 A			31-12-1991
WO 9950256 A	07-10-1999	AU 3599799 A			18-10-1999
		BR 9909197 A			05-12-2000
		EP 1066269 A			10-01-2001
		NO 20004809 A			24-11-2000
		TR 200002761 T			22-01-2001
		US 6150360 A			21-11-2000
		EP 0945447 A			29-09-1999
WO 0027828 A	18-05-2000	AU 1046200 A			29-05-2000
		WO 0122938 A			05-04-2001
EP 945443 A	29-09-1999	AU 3599699 A			18-10-1999
		BR 9909191 A			05-12-2000
		WO 9950250 A			07-10-1999
		NO 20004810 A			26-09-2000
		TR 200002760 T			21-12-2000
		US 6197779 B			06-03-2001
		EP 0945442 A			29-09-1999